TECHBio-Techne
The financials
Bio-Techne by the numbers
Bio-Techne (TECH) reported revenue of $300M in fiscal Q1 2027 (quarter ended Sep 30, 2026), up 4.6% from the same quarter a year earlier. That came with a gross margin of 66% and net income of $28M (9.4% of revenue). For the full year FY2026, revenue was $1.22B (−0.4% year on year) and net income $182M. Its largest region in fiscal Q1 2027 was United States at $153M, 51% of the disclosed total, well ahead of EMEA, excluding UK at 25%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q1 2027 | Q1 2026 | Change |
|---|---|---|---|
| Revenue | $300M | $287M | +4.6% |
| Gross profit | $197M | $188M | +4.5% |
| Operating income | $37M | $48M | −23% |
| Net income | $28M | $38M | −26% |
| Diluted EPS | $0.18 | $0.24 | −25% |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $153M | 51% |
| EMEA, excluding UK | $74M | 25% |
| China | $29M | 9.6% |
| APAC, excluding Greater China | $22M | 7.5% |
| United Kingdom | $14M | 4.6% |
| Rest of World | $8.1M | 2.7% |
Over its last three fiscal years Bio-Techne booked income tax of 19.3% of its pretax profit, 32.2% once deferred tax is taken out, close to the 21.3% median for US companies in our tax study.
Business segments
Revenue split by geographic segment, from SEC XBRL filings.
- United States$152.7M$152.7Mvs last quarter -8.1%vs a year ago -1.7%-8.1%-1.7%
- EMEA, excluding UK$73.9M$73.9Mvs last quarter -7.9%vs a year ago +13%-7.9%+13%
- China$28.9M$28.9Mvs last quarter +7.4%vs a year ago +17%+7.4%+17%
- APAC, excluding Greater China$22.5M$22.5Mvs last quarter +1.6%vs a year ago +17%+1.6%+17%
- United Kingdom$13.7M$13.7Mvs last quarter -5.0%vs a year ago +4.0%-5.0%+4.0%
- Rest of World$8.1M$8.1Mvs last quarter -29%vs a year ago -11%-29%-11%
Biotechnology
The closest names by size in the same industry